GlassScriptPhysician profile
Michael P Ellis
NPI 1598127243
$38,190.44
in general payments reported to CMS, 2019-2025
19 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $126 · 2021: $295 · 2022: $2,349 · 2023: $22K · 2024: $11K · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,405 · Food and Beverage: $4,059 · Travel and Lodging: $3,716 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,767.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,404.50 |
| Food and Beverage | $4,059.06 |
| Travel and Lodging | $3,716.05 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $16,451.82 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $7,868.84 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Topcon Healthcare, INC. | $5,058.07 | 2024 | |
| F. Hoffmann-La Roche Ag | $2,892.16 | 2024 | Vabysmo |
| Alimera Sciences, INC. | $2,797.76 | 2020-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $1,062.64 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $423.93 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Alcon Vision LLC | $372.17 | 2019-2025 | Unity, Constellation |
| Abbvie INC. | $372.06 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $219.74 | 2022-2025 | Eylea, Eylea Hd |
| Mallinckrodt Hospital Products INC. | $197.76 | 2025 | Acthar |
| Biogen, INC. | $126.19 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $109.79 | 2020 | |
| Astellas Pharma US INC | $71.52 | 2024-2025 | Izervay |
| Allergan, INC. | $46.28 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $42.86 | 2022-2023 | Xipere |
| Coherus Oncology, INC. | $34.89 | 2024 | |
| Aerie Pharmaceuticals, INC. | $22.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.35 | 2025 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.